Gfs Advisors, LLC Bristol Myers Squibb CO Transaction History

Gfs Advisors, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 19, 2023	BUY	$57.89 - $64.73 $743,886 - $831,780	12,850 New	12,850 $745,000
Q2 2020 Jul 29, 2020	SELL	$54.82 - $64.09 $330,564 - $386,462	-6,030 Closed	0 $0
Q1 2020 May 05, 2020	SELL	$46.4 - $67.43 $4,640 - $6,743	-100 Reduced 1.63%	6,030 $336,000
Q4 2019 Jan 17, 2020	BUY	$49.21 - $64.19 $4,921 - $6,419	100 Added 1.66%	6,130 $393,000
Q1 2019 May 13, 2019	SELL	$45.12 - $53.8 $9,475 - $11,298	-210 Reduced 3.37%	6,030 $288,000
Q4 2018 Feb 12, 2019	BUY	$48.76 - $63.23 $113,610 - $147,325	2,330 Added 59.59%	6,240 $324,000
Q1 2018 May 09, 2018	SELL	$59.92 - $68.98 $778 - $896	-13 Reduced 0.33%	3,910 $259,000
Q4 2017 Feb 09, 2018	SELL	$59.94 - $65.35 $53,226 - $58,030	-888 Reduced 18.46%	3,923 $240,000
Q3 2017 Nov 07, 2017	SELL	$55.23 - $63.74 $12,316 - $14,214	-223 Reduced 4.43%	4,811 $307,000
Q2 2017 Aug 07, 2017	BUY	N/A	5,034	5,034 $280,000

2,428

1.5B

29.7M

32.2M

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $113B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

Get notified when there are updates to the investment portfolio of Gfs Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Gfs Advisors, LLC with notifications on news.